Autologous stem cell transplantation for early type 1 diabetes mellitus

Autoimmunity

Volumn 41, Issue 8, 2008, Pages 666-672

  Couri, Carlos Eduardo Barra ^a   Voltarelli, Júlio César ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cell precursors; cell preservation; cell regeneration; Diabetes mellitus; Immune intervention; Stem cell

Indexed keywords

AZATHIOPRINE; C PEPTIDE; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INSULIN; LEVOTHYROXINE; MESNA; OXYGEN; PLACEBO; PREDNISONE; T LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ALOPECIA; AUTOIMMUNE POLYENDOCRINOPATHY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL PROTECTION; CELL REGENERATION; FEBRILE NEUTROPENIA; GRAVES DISEASE; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOTHYROIDISM; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY PANCREAS TRANSPLANTATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PNEUMONIA; REVIEW; VOMITING;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN-SECRETING CELLS; YOUNG ADULT;

EID: 65449129177     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930802200208     Document Type: Review

References (40)

1. American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care, 27, pp. S5-S10.
2. Wild, S., Roglic, G., Green, A., Sicree, R. and King, H. (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 27:5, pp. 1047-1053.
3. Rubin, RR and Peyrot, M. (1999) Quality of life and diabetes. Diabetes Metab Res Rev, 15:3, pp. 205-218.
4. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:14, pp. 977-986.
5. Onkamo, P., Vaananen, S., Karvonen, M. and Tuomilehto, J. (1999) Worldwide increase in incidence of Type I diabetes-the analysis of the data on published incidence trends. Diabetologia, 42:12, pp. 1395-1403.
6. Notkins, AL and Lernmark, A. (2001) Autoimmune type 1 diabetes: Resolved and unresolved issues. J Clin Invest, 108:9, pp. 1247-1252.
7. Bennett, ST and Todd, JA (1996) Human type 1 diabetes and the insulin gene: Principles of mapping polygenes. Annu Rev Genet, 30, pp. 343-370.
8. Pozzilli, P. and Di Mario, U (2001) Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): Definition, characterization, and potential prevention. Diabetes Care, 24:8, pp. 1460-1467.
9. Petrone, A., Galgani, A., Spoletini, M., Alemanno, I., Di Cola, S, Bassotti, G., Picardi, A., Manfrini, S., Osborn, J., Pozzilli, P. and Buzzetti, R. (2005) Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev, 21:3, pp. 271-275.
10. Pozzilli, P., Mesturino, CA, Crino, A., Gross, TM, Jeng, LM and Visalli, N. (2001) Is the process of beta-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males?. Eur J Endocrinol, 145:6, pp. 757-761.
11. Palmer, JP, Fleming, GA, Greenbaum, CJ, Herold, KC, Jansa, LD, Kolb, H., Lachin, JM, Polonsky, K. S., Pozzilli, P., Skyler, JS and Steffes, MW (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: Report of an ADA workshop, 21-22 October 2001. Diabetes, 53:1, pp. 250-264.
12. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Jama, 287:19, pp. 2563-2569.
13. The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med, 128:7, pp. 517-523.
14. Bonner-Weir, S. and Sharma, A. (2002) Pancreatic stem cells. J Pathol, 197:4, pp. 519-526.
15. Swenne, I. (1992) Pancreatic beta-cell growth and diabetes mellitus. Diabetologia, 35:3, pp. 193-201.
16. Fernandes, A., King, LC Guz, Y. et al. (1997) Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology, 138:4, pp. 1750-1762.
17. Bonner-Weir, S., Trent, DF and Weir, GC (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest, 71:6, pp. 1544-1553.
18. Finegood, DT, Scaglia, L. and Bonner-Weir, S. (1995) Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes, 44:3, pp. 249-256.
19. Sako, Y. and Grill, VE (1990) Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes, 39:12, pp. 1580-1583.
20. Bernard, C., Berthault, MF, Saulnier, C. and Ktorza, A. (1999) Neogenesis vs. apoptosis As main components of pancreatic beta cell ass changes in glucose-infused normal and mildly diabetic adult rats. Faseb J, 13:10, pp. 1195-1205.
21. Bonner-Weir, S., Deery, D., Leahy, JL and Weir, GC (1989) Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes, 38:1, pp. 49-53.
22. Topp, BG, McArthur, MD and Finegood, DT (2004) Metabolic adaptations to chronic glucose infusion in rats. Diabetologia, 47:9, pp. 1602-1610.
23. Kuroda, A., Yamasaki, Y. and Imagawa, A. (2003) Beta-cell regeneration in a patient with type 1 diabetes mellitus who was receiving immunosuppressive therapy. Ann Intern Med, 139:10, p. W81.
24. Kang, EM, Zickler, PP, Burns, S., Langemeijer, SM, Brenner, S., Phang, OA, Patterson, N., Harlan, D. and Tisdale, JF (2005) Hematopoietic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp Hematol, 33:6, pp. 699-705.
25. Nelson, JL, Torrez, R., Louie, FM, Choe, OS, Storb, R. and Sullivan, KM (1997) Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl, 48, pp. 23-29.
26. Elliott, RB, Crossley, JR, Berryman, CC and James, AG (1981) Partial preservation of pancreatic beta-cell function in children with diabetes. Lancet, 2:8247, pp. 631-632.
27. Harrison, LC, Colman, PG, Dean, B., Baxter, R. and Martin, FI (1985) Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes, 34:12, pp. 1306-1308.
28. Cook, JJ, Hudson, I., Harrison, LC, Dean, B., Colman, PG, Werther, GA, Warne, GL and Court, JM (1989) Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes, 38:6, pp. 779-783.
29. Silverstein, J., Maclaren, N., Riley, W., Spillar, R., Radjenovic, D. and Johnson, S. (1988) Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med, 319:10, pp. 599-604.
30. Assan, R., Feutren, G., Sirmai, J., Laborie, C., Boitard, C., Vexiau, P., Du Rostu, H, Rodier, M., Figoni, M. Vague, P. et al. (1990) Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes, 39:7, pp. 768-774.
31. Bougneres, PF, Landais, P., Boisson, C., Carel, JC, Frament, N., Boitard, C., Chaussain, JL and Bach, JF (1990) Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes, 39:10, pp. 1264-1272.
32. Herold, KC, Hagopian, W., Auger, JA, Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, SE, Harlan, DM, Xu, D., Zivin, RA and Bluestone, J. A. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med, 346:22, pp. 1692-1698.
33. Keymeulen, B., Vandemeulebroucke, E. Ziegler, AG et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med, 352:25, pp. 2598-2608.
34. Raz, I., Elias, D. Avron, A. et al. (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet, 358:9295, pp. 1749-1753.
35. Saudek, F., Havrdova, T. Boucek, P. et al. (2004) Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud, 1:2, pp. 80-88.
36. Haller, M., Viener, H. and Brusko, T. (2007) Insulin requeirements, HbA1c, and stimulated C-peptide following autologous umbilical cord blood transfusion in children with T1D, p. A82. American Diabetes Association Publisher, Alexandria, Chicago
37. Voltarelli, JC, Couri, CE Stracieri, AB et al. (2007) Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Jama, 297:14, pp. 1568-1576.
38. Skyler, JS (2007) Cellular therapy for type 1 diabetes: Has the time come? Jama, 297:14, pp. 1599-1600.
39. Ross, LF and Philipson, LH (2007) Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus. Jama, 298:3, pp. 285-286.
40. Voltarelli, J., Couri, C. Stracieri, A. et al. (2007) Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus (reply). JAMA, 298, pp. 285-286.